Bemcentinib (R428)

N. catalogoS2841 Lotto:S284108

Stampa

Dati tecnici

Formula

C30H34N8
Peso molecolare 506.64 Numero CAS 1037624-75-1
Solubilità (25°C)* In vitro DMSO 9 mg/mL (17.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Aggiungere i solventi al prodotto singolarmente e in ordine.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml significa leggermente solubile o insolubile.
* Si prega di notare che Selleck testa la solubilità di tutti i composti internamente e la solubilità effettiva può differire leggermente dai valori pubblicati. Ciò è normale ed è dovuto a leggere variazioni da lotto a lotto.
* Spedizione a temperatura ambiente (I test di stabilità mostrano che questo prodotto può essere spedito senza alcuna misura di raffreddamento.)

Preparazione delle soluzioni stock

Attività biologica

Descrizione Bemcentinib (R428, BGB324)  un inibitore di Axl con IC50 di 14 nM, che dimostra una selettivit >100 volte maggiore per Axl rispetto ad Abl. Questo composto  anche pi di 50-100 volte selettivo per Axl rispetto a Mer e Tyro3 ed esibisce una selettivit 100 volte maggiore rispetto a InsR, EGFR, HER2 e PDGFR.
Target
Axl
(Cell-free assay)
14 nM
In vitro Bemcentinib (R428) blocks the catalytic and procancerous activities of Axl. It inhibits Axl with low nanomolar activity and blocks Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. In a recent study, this compound shows a mean IC50 dose of ∼ 2.0μM for the primary CLL B cells after 24 hours of treatment and normal B-, T-, and natural killer (NK) cells show no significant amount of cell death at this dose of R428 (2.5 μM) under similar experimental conditions.
In vivo Pharmacologic investigations reveal favorable exposure after oral administration of Bemcentinib (R428), such that treated tumors display a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, it inhibits angiogenesis in corneal micropocket and tumor models. This compound also reduces metastatic burden and extends survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis.

Protocollo (da riferimento)

Studio sugli animali:

[1]
  • Modelli animali

    MDA-MB-231-luc-D3H2LN Intracardiac Model

  • Dosaggi

    125 mg/kg

  • Somministrazione

    Oral, twice daily

Riferimenti

  • https://pubmed.ncbi.nlm.nih.gov/20145120/
  • https://pubmed.ncbi.nlm.nih.gov/21135257/

Convalida del prodotto da parte del cliente

Cetuximab-resistant cells are sensitive to therapeutic blockade of AXL activity with the AXL TKI R428. Cells were treated with vehicle (-) or indicated doses of R428 for 24 hours before harvesting whole-cell lysate and immunoblotting for the indicated proteins. α-Tubulin was used as a loading control.

Dati da [ Cancer Res , 2014 , 74(18), 5152-64 ]

Axl inhibitor promotes the apoptosis induced by ALK-TKIs. (A) After treated with crizotinib (100 nM), BGB324 (300 nM) or their combination for 48 h, cell apoptosis was determined by flow cytometry. (B) The induction of apoptosis by ceritinib (100 nM), BGB324 (300 nM) or their combination was examined. (C and D) Cells were treated with crizotinib (100 nM), BGB324 (300 nM) or their combination for 48 h, then whole-cell lysates were collected and the levels of indicated protein were analyzed by Western blot in (C) NB1643 and (D) SHSY5Y cells. *P < 0.05 for the indicated comparisons; ns, not significant.

Dati da [ Biochem Bioph Res Co , 2014 , 10.1016/j.bbrc.2014.10.126 ]

<p>B) The processing of AXL is increased by an AXL kinase inhibitor. Panc-28 cells were incubated overnight with DMSO or 150 nM R428, a selective AXL kinase inhibitor, before examining by Western blot the levels of endogenous AXL-FL and AXL-CTF (C-20; left). Levels of AXL-CTF in DAPT-treated cells were quantified as described above and unpaired Student’s t test was employed for the analysis (right). Data are shown as means±SEM (n = 4). ***P<0.001.</p>

, , FASEB J, 2017, 31(4):1382-1397

Flow cytometry analysis showing band 3/α4 integrin expression of luciferase and TET2-knockdown CFU-E cells cultured for 13 days in the presence of DMSO or 0.2 μM R428.

Dati da [ , , Blood, 2018, doi:10.1182/blood-2018-05-853291 ]

Selleck's Bemcentinib (R428) È stato citato da 142 Pubblicazioni

Pre-adaptation of stem cell-derived islet organoids to hypoxia via zinc transportation inhibition drives angiogenesis [ Cell Stem Cell, 2026, 33(4):676-694.e10] PubMed: 41932324
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy [ Cell Stem Cell, 2025, S1934-5909(25)00265-6] PubMed: 40812300
Tumor initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice [ J Clin Invest, 2025, e180893] PubMed: 39774471
Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment [ Front Immunol, 2025, 16:1601420] PubMed: 40539073
Synaptotagmin-7 deficit causes insulin hypoactivity and contributes to behavioral alterations in mice [ iScience, 2025, 28(5):112354] PubMed: 40330888
Geranylgeranyl diphosphate synthase deficiency impairs efferocytosis and resolution of acute lung injury [ Respir Res, 2025, 26(1):189] PubMed: 40380222
FRA1 drives melanoma metastasis through an actionable transcriptional network [ bioRxiv, 2025, 2025.06.07.658418] PubMed: 40661443
Directed differentiation of pancreatic δ cells from human pluripotent stem cells [ Nat Commun, 2024, 15(1):6344] PubMed: 39068220
CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer [ Nat Commun, 2024, 15(1):2818] PubMed: 38561369
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia [ Theranostics, 2024, 14(7):2656-2674] PubMed: 38773967

POLITICA DI RESO
La politica di reso incondizionato di Selleck Chemical garantisce ai nostri clienti un'esperienza di acquisto online senza problemi. Se non sei in alcun modo soddisfatto del tuo acquisto, puoi restituire qualsiasi articolo entro 7 giorni dalla ricezione. In caso di problemi di qualità del prodotto, sia relativi al protocollo che al prodotto, puoi restituire qualsiasi articolo entro 365 giorni dalla data di acquisto originale. Si prega di seguire le istruzioni seguenti per la restituzione dei prodotti.

SPEDIZIONE E CONSERVAZIONE
I prodotti Selleck vengono trasportati a temperatura ambiente. Se ricevi il prodotto a temperatura ambiente, ti assicuriamo che il Dipartimento di Ispezione Qualità di Selleck ha condotto esperimenti per verificare che la conservazione a temperatura normale per un mese non influirà sull'attività biologica dei prodotti in polvere. Dopo la raccolta, conservare il prodotto secondo le indicazioni descritte nella scheda tecnica. La maggior parte dei prodotti Selleck è stabile nelle condizioni raccomandate.

NON PER USO UMANO, DIAGNOSTICO VETERINARIO O TERAPEUTICO.